InMed Pharmaceuticals Inc. (INM) Misses Q3 EPS by 194c

InMed Pharmaceuticals Inc. (NASDAQ: INM) reported Q3 EPS of ($1.94), $1.94 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $1.26 million versus the consensus estimate of $0 .

For earnings history and earnings-related data on InMed Pharmaceuticals Inc. (INM) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Blue Owl leads $2.4B equipment financing for IREN's Canada data center
• Canada invests CAD $195M in Xanadu for quantum manufacturing